Johnson & Johnson: Our Vaccine Builds Strong Immunity

Johnson & Johnson: Our Vaccine Builds Strong Immunity Pharmaceutical company Johnson & Johnson said that the coronavirus vaccine it produced created strong immunity in clinical trials. US-based Johnson & Johnson (J&J) reported that a single dose of the vaccine named "Ad26.COV2.S" is as effective as two doses and therefore it will be easier to distribute. It was stated that the effect of Moderna and Pfizer's vaccine, which is continuing clinical trials on approximately 1000 adults, on the elderly population is not clear at the present stage. In clinical trials, it was found that the immune response in young participants was around 64 percent; It was stated that in the group over 65 years of age, the reaction was at the level of 36 percent.   It will be tested on 60 thousand people It was informed that Johnson & Johnson will test the vaccine on 60 thousand people in the last phase, and then apply for a use permit and mass production to the US Food and Drug Administration. The company's officials stated that they anticipate that the last phase, known as 3 phases, will yield results until the end of the year or the beginning of 2021, and when the studies are completed, more details will be announced on the safety and effect of the vaccine. It is known that the US pharmaceutical company Johnson & Johnson signed a $ 1 billion agreement with the US government on August 5 for the production and delivery of 100 million doses of Coronavirus (Covid-19) vaccine. Completing the 1st and 2nd stage clinical tests of the vaccine candidate named “Ad26.COV2.S” in the USA and Belgium, the company aims to produce and distribute more than 1 billion doses of vaccine next year if the 3rd phase is successful.